Biyoung Pharma Secures Tens of Millions in Pre-A+ Financing to Advance Ophthalmology and Oncology IND-Enabling Studies

Following the completion of its Pre-A round financing in May 2023,Beyang Therapeutics Co., Ltd. ("Beyang Therapeutics") recently announced that it has once again secured tens of millions of yuan in Pre-A+ round financing.。This round of investment was exclusively provided by Root Venture Partners, and the funds raised will be used to accelerate the (U.S.-China) IND registration and submission research for the first two pipelines in the ophthalmology and oncology fields promoted by Beyang Therapeutics.

Beyang Therapeutics Founder Hu QiyueExpressed: "We are very grateful for the recognition and support from Root Venture Partners. Against the backdrop of the current capital winter, we are fortunate to have completed both our Pre-A and Pre-A+ financing rounds within a year, gaining favor from multiple investment institutions. This is a tremendous encouragement and affirmation for the Beyang Therapeutics team. Based onExCEEDThe project pipeline built by the technology platform is accelerating the realization of value, fully demonstrating Best-in-Class potential. In the future, while fully promoting the development of our own pipeline, we will also expand external cooperation to provide doctors, patients, and partners with innovative drugs of greater clinical value, focusing on building Beyang Therapeutics into an innovative dream factory for new drug research and development."

Root Venture Partners Founding Partner, Wan JinStated: "China's biopharmaceuticals industry has established an ecosystem with high standards that aligns with the global market. Uncovering entrepreneurs with international perspectives and a willingness to innovate, as well as high-quality assets, is the mission Root Venture Partners is currently undertaking. The pipeline of projects developed by Beyang Therapeutics, using their proprietary fusion of computational simulation and wet-lab experimental technology, demonstrates potential for competing in the international market. We are delighted to invest in Beyang Therapeutics and look forward to their products showcasing value in clinical settings soon."

Beyang Therapeutics Co., Ltd. was founded in April 2021, with its headquarters located in the BioBAY biopharmaceutical park in Suzhou Industrial Park. The company has successfully builtExCEEDTechnical Platform: By integrating computational simulation with wet-lab techniques, the platform strengthens early-stage drug discovery capabilities across three core areas—molecular design, drug-likeness optimization, and biological evaluation. This approach continuously generates projects with Best-in-Class potential, establishing an innovative powerhouse for new drug development. The company’s core team members average over 20 years of practical experience in combining new drug R&D and computational simulation within pharmaceutical enterprises both in China and internationally. Collectively, they have made significant contributions to the research and development of more than 20 clinical-stage drug candidates or marketed drugs. Beyang Therapeutics focuses on ophthalmology and oncology, with multiple self-developed pipelines already established. The first two projects (BT01001 and BT01002) have demonstrated robust Best-in-Class potential in preclinical head-to-head studies and are currently advancing through IND registration studies in both China and the U.S.

Root Venture Partners ("Yuanjin Ventures") was established in July 2022. Yuanjin Ventures focuses on early-stage venture capital investment in the healthcare industry, committed to discovering high-growth opportunities amid industry development and transformation. By investing, it brings together capital, technology, and talent, collaborating with entrepreneurs in value creation to deliver consistently excellent returns for investors. The investment team at Yuanjin Ventures has extensive experience in strategic development, capital operations, and human resources of biopharmaceutical startups.